Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate CycleThe Motley Fool • 10/17/26
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026PRNewsWire • 10/17/26
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarket Watch • 10/15/26
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 10/14/26
5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income24/7 Wall Street • 10/13/26
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePRNewsWire • 10/11/26
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.The Motley Fool • 10/11/26
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That HappensThe Motley Fool • 10/09/26
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks24/7 Wall Street • 10/09/26
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerZacks Investment Research • 10/08/26
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong24/7 Wall Street • 10/07/26
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCPRNewsWire • 10/07/26